Background {#Sec1}
==========

Malaria infection is still a big challenge for public health; around 214 million new cases of malaria worldwide occurred in 2015 (range 149--303 million) \[[@CR1]\]. *Plamosdium falciparum* is responsible for the most severe cases of malaria and the greatest number of deaths. Detection and monitoring of severe cases are remaining issues for patient treatment \[[@CR2]\].

Galectin-9 (Gal-9) is member of the galectin family of β-galactoside-binding animal lectins with a conserved carbohydrate recognition domain (CRD) \[[@CR3]\]. Gal-9 was first described as an eosinophilic chemoattractant \[[@CR4]\]. Gal-9 is presumed to bind a variety of molecules including glycoproteins and glycolipids of immune cells and pathogens \[[@CR5]\]. These binding properties exert a variety of physiological and pathological functions such as cell differentiation, adhesion, aggregation, and cell death \[[@CR6]\]. The elevation of plasma Gal-9 levels during acute human immunodeficiency virus (HIV) infection followed by a rapid decrease after anti-retroviral therapy was reported \[[@CR7], [@CR8]\]. Increase in plasma Gal-9 has also been seen during acute dengue virus infection \[[@CR9]\]. Gal-9 inhibits production of several pro-inflammatory cytokines (TNF, IL-6, IL-1α) and enhances production of IL-10 \[[@CR10]\]. These cytokines are believed to be involved in pathophysiology of malaria \[[@CR11]--[@CR13]\]. Recent findings of co-inhibitory or immune checkpoint receptors have been giving a novel insight into immune regulation. Because these receptors have a critical role in the maintenance of immune homeostasis: their expression on effector T cells ensures the proper contraction of effector T cells responses and their expression on regulatory T (Treg) cells guarantees the proper function of Treg cells to control effector T cells \[[@CR14], [@CR15]\].

It has been reported that PD1, a co-inhibitory receptor play a major role for inactivating a protective immunity in malaria infection in mice \[[@CR16]\]. Gal-9 binds to T cell immunoglobulin and domain 3 (Tim-3) a co-inhibitory receptor, and that binding can ameliorate experimental autoimmune encephalomyelitis (EAE) by inducing cell death in Tim-3^+^ Th1 cells \[[@CR17], [@CR18]\]. Gal-9 also regulates activated CD8+ T cells \[[@CR19]\], which increase during malaria \[[@CR20]\]. Activation of CD8+ T cells these cells is considered as a risk factor of anemia in severe malarial \[[@CR21]\]. These emerging regulatory activities of Gal-9 involving co-inhibitory receptors took us to investigate Gal-9 in malaria, though how Tim-3 functions to determine effector T cell responses is not yet well clarified \[[@CR15]\]. Recently expression of Gal-9 and Tim-3 was demonstrated in lung, mediastinal lymph nodes and liver tissues in murine malaria model \[[@CR22], [@CR23]\]; however, the plasma levels of Gal-9 in human malaria patients has not been evaluated yet.

In this study, the plasma levels of Gal-9 in malaria patients were measured at three time points (days 0, 7 and 28) to examine its kinetics and association with cytokines, chemokines and clinical parameters.

Methods {#Sec2}
=======

Study subjects {#Sec3}
--------------

Samples at three time points (day 0, day 7 and day 28) were obtained from 50 malaria patients, of which 41 were acute uncomplicated falciparum malaria (UM) and nine were severe falciparum malaria (SM) cases. The median age of patients enrolled was 23 (range 15--50) years old. There were 29 males and 21 females. Patient body temperatures were \>38.5 °C upon admission. Diagnosis was performed by thick and thin blood smear in patients presenting malaria symptoms and malaria cases were defined by positive asexual forms of *P. falciparum*. Categorization of malaria cases was performed using WHO criteria \[[@CR24]\]. Blood was collected in EDTA-containing tubes and centrifuged at 3000 rpm for 10 min. Obtained plasma was aliquoted and stored at −80 °C until use. On day 0, blood was collected and all patients were initiated on treatment with artemisinin-based combination therapy (ACT). Patients were followed up until day 28 according to the protocol.

Clinical processing {#Sec4}
-------------------

At enrollment, clinical information was taken and entered in standardized forms. Clinical and bedside physical examinations were performed. Complete blood counts (CBC) in addition to kidney and liver function tests were examined.

Biomarker measurement {#Sec5}
---------------------

Gal-9 concentration in plasma was measured using an ELISA (Galpharam Co. Ltd., Takamatsu, Japan) as previously described \[[@CR9]\]. Microplates with 96 wells were coated with anti-human Gal-9 monoclonal antibody (9S2-3), blocked with 5 % fetal bovine serum in PBS, then incubated with the test sample (eightfold diluted plasma) for 1 h at RT with continuous shaking at 225 rpm. After several washing steps, Gal-9 remaining in the wells was recognized by a polyclonal anti-human Gal-9 antibody conjugated with biotin using EZ-Link Sulfo-NHS-Biotin reagent (Pierce). Quantification was performed by incubating wells with streptavidin-conjugated horseradish peroxidase (Invitrogen, Tokyo, Japan) and the colorimetric substrate tetramethylbenzidine (KPL, Gaitherburg, MD); then, the optical density was read with a microplate spectrophotometer (Bio-Rad).

Thirty-eight cytokine and chemokine species were measured using a commercially available kit (Milliplex Human Cytokine and Chemokine multiplex assay kit, Merck Millipore, Billerica, MA, USA) by Luminex methods as previously \[[@CR9]\]. The assay was performed according to manufacturer's instructions and the concentrations of cytokines/chemokines were calculated by comparing reads with a 5-parameter logistic standard curve using a Bioplex-200 instrument (Bio-Rad, Hercules, CA, USA).

Statistical analysis {#Sec6}
--------------------

The distribution of data did not generally show a normal distribution by using the Kolmogorov--Smirnov test. Therefore, the data were expressed as the median and range. Friedman test, a non-parametric statistical test, was used to assess differences of Gal-9 and other biomarkers levels between different time points. The Mann--Whitney test, also a non-parametric test, was used to assess differences in biomarkers and clinical parameters between SM and UM cases. Correlation was assessed using Spearman's rank correlation coefficient test. These statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, San Diego, CA, USA). A significant difference was assumed when *P* \< 0.05.

Results {#Sec7}
=======

Clinical parameter profiles in uncomplicated and severe malaria cases {#Sec8}
---------------------------------------------------------------------

The median of haemoglobin were not significantly different between UM and SM cases at day 0 (Table [1](#Tab1){ref-type="table"}). However, at day-7, the median haemoglobin level in SM cases was significantly lower compared to UM cases. Direct bilirubin median levels were higher in SM cases compared to UM cases at day 0 and day 7. Median platelet level was significantly lower at day 0 in SM compared to UM cases. The median levels of creatinine, BUN and AST level were significantly higher in SM cases compared to UM at day 0. Median levels of sodium and bicarbonate were lower in SM cases compared to UM at day 0 (Table [1](#Tab1){ref-type="table"}).Table 1Clinical parameters of uncomplicated and severe malaria patients from day-0 to day-7Clinical parameters^a^Day 0Day 7UMSMUMSMHaemoglobin (g/dL)11.9 (6--14.4)11 (6.3--14)^b^ ns10.3 (6.3--14.2)8.6 (6.3--9.7)^c,^ \*\*Direct Bilirubin (mg/dL)0.29 (0.06--2.6)0.98 (0.3--5.7)^b,^ \*\*\*0.12 (0.06--0.55)0.235 (0.1--0.64)^c,^ \*Platelets (cell/μL)85.5 (16--502)27 (16--59)^b,^ \*\*249.5 (138--563)226 (130--429)^c^ nsCreatinine (mg/dL)1 (0.6--1.6)1.25 (1--6.4)^b,^ \*\*0.8 (0.5--1.3)0.775 (0.6--1.15)^c^ nsBUN (mg/dL)19.5 (6--56.7)44.5 (20.3--154.4)^b,^ \*\*\*\*8.5 (4.5--16.5)9 (5--12)^c^ nsAST (U/L)35 (18--230)80 (40--295)^b,^ \*\*34.00 (12.00--97)43.50 (20--295)^c^ nsSodium (mmol/L)135 (118--147)129.5 (118--144)^b,^ \*140 (136--146)138 (134--144)^c^ nsBicarbonate (mmol/L)22 (15--23)20 (17--25)^b,^ \*22 (20--26)21 (21--24)^c^ nsMann--Whitney non-parametric test was used to assess differences between parameters*UM* uncomplicated malaria; *SM* severe malaria\*\*\*\* P \< 0.0001, \*\*\* P \< 0.001, \*\* P \< 0.01, and \* P \< 0.05^a^Median and range^b^Compared UM to SM on day 0^c^UM to SM 7

Kinetic changes in plasma levels of galectin-9 and description of its levels in uncomplicated and severe malaria cases {#Sec9}
----------------------------------------------------------------------------------------------------------------------

Median plasma levels of Gal-9 were significantly elevated in malaria patients at day 0 (686 pg/mL) compared to day 7 (398 pg/mL) and day 28 (243 pg/ml). The median levels of Gal-9 on day 7 was found to be higher compared to day 28 but the difference was not significant (Fig. [1](#Fig1){ref-type="fig"}a). Median levels of Gal-9 were significantly higher in SM compared to UM at day 0 (923 pg/mL vs 617 pg/mL) and day 7 (659 pg/mL vs 348 pg/mL*).* At day 28, there was no significant difference in the Gal-9 levels between the two groups (Fig. [1](#Fig1){ref-type="fig"}b).Fig. 1Plasma galectin-9 levels in patients with malaria. **a** Galectin-9 kinetics from day 0 to day 28. **b** Comparison between uncomplicated and severe cases, results are expressed as the median. *UM* uncomplicated malaria, *SM* severe malaria

Kinetic changes of other biomarkers {#Sec10}
-----------------------------------

Among the 38 biomarkers measured, pro-inflammatory cytokines of IFN-α2, IL-1α, TNF and IL-6, Th1-related cytokine of IFN-γ, regulatory cytokines of IL-10 and IL-1Ra, growth cytokines of G-CSF, GM-CSF, EGF, FGF-2 and VEGF, and chemokines of IP-10, MIP-1α, MIP-β, MCP-1, IL-8, eotaxin, GRO, Fractalkine and MDC were detectable. All of them showed significant difference at day 0 compared to day 7 or day 28 except VEGF, MIP-1α, eotaxin and GRO (Table [2](#Tab2){ref-type="table"}). In addition, the levels of MDC, EGF and sCD40L showed significant increase at day 28 compared to day 0 (Table [2](#Tab2){ref-type="table"}).Table 2Kinetic changes of biomarkers from day-0 to day-28BiomarkersDay-0 (median)Day-7 (median)Day-28 (median)Pro-inflammatory cytokines IFN-α219.95 (2.980--173.9)^a,^ \*\*\*\*11.92 (2.980--79.51)^b^ ns8.87 (2.980--70.26)^c,^ \*\*\*\* IL-1α25.32 (2.77--69.02)^a,^ \*\*10.28 (2.44--103.4)^b^ ns9.63 (2.44--124.9)^c,^ \*\* TNF36.54 (3.91--185.5)\*\*\*\*10.72 (3.83--74.45)^b^ ns9.035 (3.89--74.45)^c,^ \*\*\*\* IL-655.11 (4.240--1814)^a^ ns7.57 (4.74--77.81)^b^ ns11.51 (4.74--77.81)^c,^ \*\*Th1-related cytokines IFN-γ28.6 (3.44--616)^a,^ \*\*\*\*10.3 (3.14--185.2)^b^ ns9.2 (3.44--150)^c,^ \*\*\*\*Regulatory cytokines IL-10549 (7.94--2321)^a,^ \*\*\*\*72.66 (3.12--281.9)^b,^ \*20.54 (3.390--2576)^c,^ \*\*\*\* IL-1Ra109.8 (20.47--1897)^a,^ \*\*\*\*31.85 (5.47--1358)^b^ ns19.64 (3.68--595.4)^c,^ \*\*\*\* sCD40L851 (70.01--18,117)^a,^ \*\*\*\*24,316 (96.21--297,336)^b^ ns1762 (54.78--200,426)^c,^ \*\*\*\*Growth cytokines G-CSF65.85 (6.66--182)^a,^ \*\*\*\*20.1 (5.38--197)^b^ ns18.98 (3.93--132.9)^c,^ \*\*\*\* GM-CSF15.23 (4.420--180)^a,^ \*8.9 (3.810--95)^b^ ns6.54 (3.090--85.38)^c,^ \*\*\*\* EGF13.72 (4.060--56.37)^a,^ \*23.6 (4.060--482.4) 8^b^ ns42.17 (6.4--344)^c,^ \*\*\*\* FGF-237.05 (13.04--507)^a^ ns35.51 (8.12--289.2)^b,^ \*\*27.29 (4.59--171.8)^c,^ \*\*\*\* VEGF104.1 (23.5--2204)^a^ ns99.74 (2.24--1754)^b^ ns77.51 (18.07--3426)^c^ ns TGF-α4.69 (0.63--21.95)^a,^ \*4.02 (0.29--34.2)^b^ ns3.18 (0.44--10.49)^c,^ \*Chemokines IP-103036 (155--8700)^a,^ \*\*\*\*671.8 (28.54--1354)^b,^ \* ns449 (110.2--6002)^c,^ \*\*\*\* MIP-1α25.11 (3.750--85.07)^a^ ns12.11 (3.780--216)^b^ ns9.675 (3.47--144.7)^c^ ns MIP-1β50.8 (13.23--199.8)^a,^ \*\*\*\*24.78 (4.950--172.5)^b^ ns25.42 (4.26--187.2)^c,^ \*\*\*\* MCP-1591.1 (40.67--9148)^a,^ \*\*\*\*228.2 (50.68--462.7)^b,^ \*\*\*323.9 (52.06--1049)^c,^ \* IL-835.15 (3.49--227.8)^a,^ \*19.82 (4.05--604)^b^ ns10.46 (3.65--564)^c,^ \* Eotaxin161.3 (21.35--1840)^a^ ns109.4 (6.54--264.5)^b^ ns122 (27.25--327)^c^ ns GRO684.6 (184.5--1701)^a^ ns806.3 (288.8--2962)^b^ ns799.3 (238.8--1902)^c^ ns Fractalkine77.84 (12.51--546.4)^a,^ \*\*\*\*25.36 (5.97--533.2)^b^ ns25.79 (2--340)^c,^ \*\*\*\* MDC284.2 (29.29--1049)^a^ ns317.8 (64.74--1595)^b,^ \*\*\*\*502.4 (75.40--801.5)^c,^ \*\*\*\*Results are shown in median levels with rangeFriedman test was used to assess differences between days\*\*\*\* P \< 0.0001, \*\*\* P \< 0.001, \*\* P \< 0.01, and \* P \< 0.05^a^Day 0 vs day 7^b^Day 7 vs day 28^c^Day 0 vs day 28

Association of galectin-9 with various biomarkers {#Sec11}
-------------------------------------------------

Numerous cytokines and chemokines were correlated with Gal-9 levels in malaria patients at day 0 (Table [3](#Tab3){ref-type="table"}). At day 0, IFN-α2 was positively associated with Gal-9 only in SM cases (r~s~ = 0.82). TNF and IL-6 were positively correlated with Gal-9 in both UM (r~s~ = 0.57 and r~s~ = 0.36, respectively) and SM cases (r~s~ = 0.83 and r~s~ = 0.73, respectively). IFN-γ was positively associated with Gal-9 in both UM (r~s~ = 0.33) and SM cases (r~s~ = 0.75) (Table [3](#Tab3){ref-type="table"}). IL-10 and IL-1Ra were positively associated with Gal-9 in both UM (r~s~ = 0.43 and r~s~ = 0.31, respectively) and SM cases (r~s~ = 0.82; and r~s~ = 0.83, respectively).Table 3Correlation of galectin-9 with cytokines and chemokines at day 0BiomarkersGalectin-9UMSMr~s~*P* valuer~s~*P* valueIFN-α20.21ns0.820.01TNF0.570.00010.830.008IL-60.360.030.730.03IFN-γ0.330.040.750.02IP-100.40.0090.65nsIL-80.440.0040.880.0031IL-100.430.0040.820.01IL-1Ra0.310.050.830.008G-CSF0.350.030.90.002MIP-1β0.320.040.880.003MCP-10.320.040.55nsFractalkine0.27ns0.720.04Correlation was calculated using a non-parametric Spearman's correlation test*UM* uncomplicated malaria; *SM* severe malaria

In addition, Gal-9 was also correlated significantly with G-CFS and MIP-1β in both UM (r~s~ = 0.35 and r~s~ = 0.32, respectively) and SM cases (r~s~ = 0.9 and r~s~ = 0.88, respectively). Gal-9 also correlated with MCP-1 in UM group (r~s~ = 0.32) and Fractalkine in SM cases (r~s~ = 0.72) (Table [3](#Tab3){ref-type="table"}).

Association of plasma galectin-9 with clinical parameters of malaria infection {#Sec12}
------------------------------------------------------------------------------

Gal-9 levels on day 0 were negatively correlated with albumin (r~s~ = −0.69), and were positively correlated with creatinine (r~s~ = 0.44) and BUN (r~s~ = 0.45) in the UM cases. The lack of correlation between these kidney parameters and Gal-9 in SM cases might be due to the small number of cases in that group (nine patients). Among the electrolytes tested, sodium levels were negatively associated with Gal-9 levels (r~s~ = −0.48) also only in the UM cases. Chloride levels were negatively associated with Gal-9 in both UM (r~s~ = −0.46) and SM cases (r~s~ = −0.73) (Table [4](#Tab4){ref-type="table"}). Furthermore, the Gal-9 median level in patients with BUN/creatinine ≥20 (mg/dL) (pre-renal azotaemia) was significantly higher than those with BUN/creatinine \<20 (mg/dL) at day 0 (817.3 vs 576.2 pg/mL) but not at day 7 (Fig. [2](#Fig2){ref-type="fig"}).Table 4Correlation between galectin-9 and clinical parametersClinical parameterGalectin-9UMSM*r* ~*s*~*P* value*r* ~*s*~*P* valueAlbumine−0.69\<0.0001−0.29nsCreatinine0.440.0050.32nsBUN0.450.0040.43nsAST0.460.0030.55nsSodium−0.480.005−0.25nsChloride−0.460.006−0.730.04Correlation was calculated using a non-parametric Spearman's correlation test. *r* ~*s*~ value represents correlation coefficient. *P* value represents significance level*UM* uncomplicated malaria; *SM* severe malariaFig. 2Comparison of galectin-9 levels on the basis of BUN/creatinine ratio **a** distribution of Gal-9 on day 0 according  BUN/creatinine. **b** distribution of Gal-9 on day 7 according to BUN/creantinine on day-0. Mann--Whitney non-parametric test was used to assess significances. Results are expressed as the median

Discussion {#Sec13}
==========

This study revealed the presence of Gal-9 in plasma in malaria patients and showed that plasma levels of Gal-9 accurately reflect the status of inflammation and recovery during malaria infection for the first time though the tissue expression of Gal-9 and Tim-3 was demonstrated in murine malaria model \[[@CR21], [@CR22]\]. The elevation of Gal-9 was reported in other acute and non-acute infectious diseases such as dengue virus infection (median level was 1525 pg/mL), leptospirosis (616 pg/mL) \[[@CR9]\], acute HIV infection (\~2300 pg/mL) \[[@CR8]\] and active tuberculosis (200 pg/mL) \[[@CR25]\]. Detailed analysis with clinical parameters in dengue virus infections showed its association with the clinical severity. Gal-9 exerts its pivotal immunomodulatory effects by inducing apoptosis or suppressing effector functions via engagement with its receptor, Tim-3 a co-inhibitory receptor, though how Tim-3 functions to determine effector responses have not been clarified, yet \[[@CR14], [@CR15]\]. The versatile activities of Gal-9 was attributed by dual activities of the molecule, anti-microbial as well as anti-inflammatory activities \[[@CR26]\].

It has been suggested that Gal-9 production might be stimulated by the response of mounting Th1 cells that occurs during *P. falciparum* infection, and produced Gal-9 was assumed to inhibit their activation \[[@CR10], [@CR14]\]. This may explain the correlation seen in this study between Gal-9 and inflammatory cytokines (IFN-γ, TNF, IFN-α and IL-6) and chemokines (MIP-1β, MCP-1 and Fractalkine) at day 0. It was proposed that the levels of TNF and IL-6 are indicators of malaria severity \[[@CR11]\]. This association of these molecules with Gal-9 in both UM and SM cases supports the idea of Gal-9 as a severity marker in malaria infection. In fact, Gal-9 levels correlated positively with kidney parameters and inversely with electrolytes.

The correlation of Gal-9 with IL-10 could be related to the effect of Gal-9 on differentiation of naïve T cells to Gal-9^+^ ThGal and Treg, which express high levels of IL-10 mRNA \[[@CR27]\]. Though both Gal-9 and IL-10 were proposed to have anti-inflammatory properties, it is known that IL-10 production is impaired in SM compared with UM as reported elsewhere \[[@CR28]\]. Another anti-inflammatory cytokine IL-1Ra levels correlated with Gal-9 both in UM and SM cases and IL-1Ra was found to be correlated with parasitemia \[[@CR29]\]. In malaria, a variety immune cells are known to be activated such as CD8+ T, CD4+ T and NK cells \[[@CR30]--[@CR32]\], and their function can be regulated or impaired by Gal-9 in vitro \[[@CR19], [@CR33]\]. However, it is difficult to demonstrate if the released Gal-9 could constrain immune response through the Gal-9/Tim-3 pathway \[[@CR19]\]. Gal-9 shares the receptor Tim-3 with high mobility box group-1 (HMBG-1), an inflammation mediator \[[@CR14], [@CR34]\]. HMGB-1 elevation was reported an as informative prognostic marker for disease severity in human severe malaria \[[@CR35]\]. In contrast to the apoptotic effect of Gal-9 on T cells \[[@CR14]\], HMGB-1 has been described as having proliferation effects by binding through HMGB-1/Tim-3 and HMGB-1/RAGE on T cells \[[@CR36], [@CR37]\]. The differential roles of these two ligands (HMGB-1 and Gal-9) in controlling the immune response against parasites should be clarified in future studies.

Beside immune modulatory activities, Gal-9 is released from infected or damaged cells, and could act as danger signal molecules \[[@CR9]\], by initiating inflammation as reported in murine respiratory tularaemia \[[@CR38]\]. Moreover the Tim-3-Gal-9 expression was found to be elevated in acute lung injury in a murine malarial model \[[@CR22]\].

The released Gal-9 can also bind to galactosides of pathogens, pathogen-associated molecular pattern (PAMP), as pathogen recognition receptors (PRRs), as shown recognition of the *Leishmania major* Poly-β-galactosyl epitope by Gal-9 \[[@CR39]\]. Future Investigation on the biological roles of Gal-9 in malaria infection would be necessary.

Conclusions {#Sec14}
===========

Taken together, this study shows an increase of plasma Gal-9 levels during malaria infection, which is capable of identifying severe cases, and is tracking the inflammation process. Therefore, it may be used as a novel biomarker of malaria infection.
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